“geoffrey-porges” Archives

in
Entry Author Date Location
Vertex Stops Test of Rare Disease Drug, Dimming Pipeline Prospects 10/15/20 Boston
AbbVie Strikes Deal for I-Mab Drug With a Potential Edge in CD47 Chase 09/04/20 National
Moderna Publishes Early COVID-19 Vaccine Data, Preps for Phase 3 Test 07/15/20 Boston
Gilead Gains Foothold in Solid Tumors With $375M, 10-Year Arcus Bio Pact 05/27/20 San Francisco
Alexion Pharma Boosts Blood Drug Lineup With $1.4B Deal for Portola 05/05/20 Boston
GSK and Sanofi Team Up on COVID-19 Vaccine, Aim for Clinic This Year 04/14/20 National
Acceleron Drops Drug for Rare Muscle Disease After Mixed Phase 2 Data 03/10/20 Boston
Third Time’s the Charm as Acceleron Drug Shows Early Promise in PAH 01/28/20 Boston
Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug 01/13/20 National
ResTORbio’s Respiratory Drug Flunks Phase 3 Test, Shattering Shares 11/15/19 Boston
Biogen Reverses Course on Alzheimer’s Drug Analysis, Plans FDA Filing 10/22/19 Boston
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More 10/01/19 National
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More 09/27/19 National
Patent Challenge to Alexion Proceeds, But No Amgen Biosimilar Yet 08/30/19 Boston
Celgene to Sell Blockbuster Drug to Amgen for $13B to Close BMS Deal 08/26/19 New York
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More 08/02/19 National
Bio Roundup: Leiden’s Exit, Depression Data, a New Pricing Bill & More 07/26/19 National
As Castle Bio Jumps on IPO Train, Industry Trends Suggest Slowdown 07/25/19 National
Gilead Ups Stake in Galapagos With $5B Deal to Jumpstart Its R&D 07/15/19 San Francisco
Sequencing Firm Adaptive’s $300M IPO Comes With Pharma Ambitions 06/27/19 Seattle
ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More 06/05/19 National
Biogen, Taking Its Crisis “Seriously,” Keeps Focus on Neuroscience 04/24/19 Boston
The Life, Troubles, and Celgene Legacy of Deal Guru George Golumbeski 03/11/19 National
All Eyes on Biogen as Roche Alzheimer’s Drug Flunks Final Test 01/30/19 National
In a Huge Biopharma Shakeup, Bristol-Myers to Buy Celgene For $74B 01/03/19 National
With New Results, FibroGen’s Anemia Pill Inches Closer to FDA Review 12/20/18 San Francisco
15 for ’19: Key Clinical Data to Watch for Next Year (Part 1) 12/17/18 National
Roche Vet O’Day Tapped to Shape Gilead’s Future as Hep C Sales Fall 12/10/18 San Francisco
BCMA Day: At ASH ‘18, Cell Therapies For Myeloma Take Center Stage 12/04/18 National
ASH 2018: Three Up, Two Down as Big Blood Disease Meeting Rolls On 12/03/18 National
Page 1 of 2 next page »